Med School: Separating Hype from Hope in Genome Science

Genomic discoveries were supposed to transform medicine and move us to a new vision of preventive health care. But 15 years after the Human Genome Project was complete, that still hasn’t happened. Meanwhile, direct-to-consumer genetics companies are bypassing health care providers to market ancestry, disease risk, diet, exercise and even dating and wine applications directly to the public. Robert Green, one of the world’s leaders in generating the evidence-base for genomic medicine, describes what's right and what’s wrong with the genomic revolution, and how we can realize the promise of precision medicine for all.
(Underwritten by America's Biopharmaceutical Companies)

Speakers: Robert C. Green
Festival: Spotlight Health 2018

Watch and Listen: Health

The Aspen Institute’s Health Innovators Fellows are industry leaders selected for their entrepreneurial approaches to... See more
Artificial intelligence, which recognizes patterns in data, images, and sound, is poised to move from the laboratory to... See more
The Veterans Health Administration, which serves nine million vets, has come under fire for long delays in providing... See more
Federal funds could not be used to pay for sugar-sweetened beverages under the Supplemental Nutrition Assistance... See more
Cancer is on the rise in Africa, with the World Health Organization predicting that by 2020, it will take the lives of... See more
Community health workers bring lifesaving care to hard-to-reach locations. More than one billion people inhabit areas... See more

Pages